Acceptability of web-based video consultations in patients with CML
Research type
Research Study
Full title
An acceptability study for the use of web-based video consultations in patients receiving lifelong treatment for chronic myeloid leukaemia patients at University College London Hospital, London, UK
IRAS ID
236595
Contact name
Tin Wai Terry Ng
Contact email
Sponsor organisation
University College London
Clinicaltrials.gov Identifier
Z6364106/2018/05/68 health research, UCL Data Protection Registration
Duration of Study in the UK
0 years, 4 months, 31 days
Research summary
For cancer patients, travelling to their hospital appointments can be difficult because their treatment can make them feel tired and unwell. It can also be expensive for them. If patients miss their appointments, it costs the NHS money and may affect their treatment outcome, making their condition harder to manage. If patients are able to have their check-ups (follow-up appointments) with their medical team without going to the hospital, this could improve patient experience and outcomes, as well as helping the NHS run more effectively.
The project aims to find out if patients who are receiving treatment for chronic myeloid leukaemia (CML) would find it acceptable to have their follow-up appointments using web-based video calling.
This will be done by conducting interviews with individual patients treated by University College London Hospital (UCLH) and also by running a focus (discussion) group(s) with patients who receive treatment elsewhere so we can compare the opinions of UCLH patients with those of the wider CML population. Patients will be asked for their opinions about: what they feel they need at follow-up consultations and the use of web-based video consultations for their follow-ups with their doctor, nurse and/or pharmacist instead of at the hospital. They will also complete a questionnaire about their current model of follow-up consultations.
Patients will be at least 18 years old, and will have received treatment for CML for at least 12 months. They will have consented to take part. Patients will be identified with the support of Bloodwise, CML Support, any other CML related support groups/charities and the UCLH CML Care Team.
The results will inform the UCLH Pharmacy Cancer Team as to whether further work in this area needs to be carried out. This could involve asking the opinions of healthcare professionals or opinions of patients with other cancers.
REC name
London - London Bridge Research Ethics Committee
REC reference
18/LO/1532
Date of REC Opinion
3 Sep 2018
REC opinion
Favourable Opinion